Company intelligence / Profile preview

Espad Pharmed

Ownership: Private
Employees: ~374
Development stage: Commercial

Overview

Currently conducting clinical trials comparing their Lunaphil Ultra (Hyaluronic Acid) product with Juvederm Ultra 4® for treating nasolabial folds, and testing AbobotulinumtoxinA in a non-inferiority clinical trial. The Lunaphil Ultra trial is a randomized, double-masked, active controlled study with 104 participants[4]. The AbobotulinumtoxinA trial is scheduled to continue until April 26, 2025[6].

Therapeutic areas: Dermatology
Modalities: Hyaluronic acid fillersAbobotulinumtoxinA
Industry: Biotech

Drug pipeline

6 assets

Abobotulinumtoxin A

Approved

5 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Espad Pharmed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Espad Pharmed.

Explore the full profile